Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock

by NASDAQ Market News May 19, 2020

NASDAQ Market News
Click here to email author

FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer

Cellectis Appoints Biopharma Veteran Leopold Bertea as Senior Vice President of Technical Operations – Europe

Ads